A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback